GLP-1 maintenance phase for PCOS: what the evidence says

What did @branneisha actually say?

After nearly four years on a GLP-1 medication and almost two years in what she calls maintenance, @branneisha made a pretty specific claim: that nobody talks about what actually happens after you hit your goal weight on one of these drugs. She says maintenance requires a total mindset shift, that the calorie-deficit logic you used to lose weight "is not going to work in maintenance," and that people either keep losing past their goal or get too relaxed and regain. She's not citing studies. She's describing her own lived experience. But that doesn't mean she's wrong.

The video is personal, messy, and a little hard to follow, which is honestly appropriate for a topic that clinical researchers are still actively trying to sort out. She's not making dramatic medical claims. She's describing a real, documented problem in plain language.

Does the science back this up?

More than most TikTok health content, yes. The challenge of weight maintenance on GLP-1 receptor agonists is real and increasingly well-documented, even if the solutions aren't settled yet.

The STEP 4 trial (Rubino et al., 2021, JAMA) is the clearest evidence here. Participants who stopped semaglutide after 20 weeks regained about two-thirds of their lost weight within a year. That study didn't look at maintenance dosing strategies, but it made the rebound problem impossible to ignore. A 2023 follow-up analysis from Wilding et al. in Diabetes, Obesity and Metabolism found that continuous treatment was necessary to sustain weight loss, and that "plateaus" during maintenance weren't failures but expected physiological states. The body actively defends its higher weight set point, a phenomenon sometimes called "adipostatic resistance." Her instinct that what worked during active weight loss won't work the same way in maintenance has real biological backing.

What did they get right, and what's shakier?

She gets a lot right. The observation that maintenance on GLP-1s is under-discussed is accurate. Most clinical trials are designed around weight loss endpoints, not long-term weight stability. The FDA approval data for semaglutide (Wegovy) and tirzepatide (Zepbound) focused on 68-week and 72-week outcomes, not year two or three. Clinicians prescribing these drugs for maintenance are genuinely working with thinner evidence than they'd like.

Her framing that people need to "be okay with having more" is vague but points at something real: caloric needs shift after significant weight loss, partly because of metabolic adaptation, and patients often need to increase intake to avoid continued unintended weight loss. This is documented in the metabolic adaptation literature (Rosenbaum and Leibel, 2010, New England Journal of Medicine).

The shakier part is the implied idea that maintenance is purely a mindset problem. It's also a pharmacology problem. Dose, drug choice, and individual response all matter, and no amount of mindset work replaces that clinical management. She doesn't say otherwise explicitly, but the framing could lead viewers to think they just need to think differently rather than work with a prescriber.

What should you actually know?

GLP-1 maintenance is a real clinical gap, not a personal failing or a content gap. Here's what the evidence actually says.

• Weight regain after stopping GLP-1 therapy is the norm, not the exception. The STEP 4 data showed an average 6.9% body weight regain within 52 weeks of discontinuation.
• Metabolic rate drops after significant weight loss, independently of the drug. This isn't new information, but it means maintenance calories are lower than pre-diet calories, sometimes substantially.
• There is no standardized clinical protocol for GLP-1 maintenance dosing. Some clinicians step down doses; others hold steady. The data is sparse, and practice varies widely.
• PCOS, which @branneisha tags, adds another variable. Insulin resistance patterns in PCOS may affect how the body responds to reduced GLP-1 stimulation over time, though this specific intersection is understudied.
• If you are in maintenance on a GLP-1 and feeling confused, that is clinically expected. Talk to your prescriber about dose adjustments, not TikTok creators, including this one.